Lead Compound Initial
Preclinical Phase 1 Phase 2 Phase 3 Affiliate Company 1

PCN-101 /

Treatment-Resistant Depression
Perception Neuroscience

RL-007 /

Cognitive Impairment Associated With Schizophrenia
Recognify Life Sciences

DMX-1002 /

Opioid Use Disorder
DemeRx IB

GRX-917 /

Generalized Anxiety Disorder
GABA Therapeutics

NN-101 /

Mild Traumatic Brain Injury

KUR-101 /
Deuterated Mitragynine

Opioid Use Disorder

EMP-01 /
MDMA derivative

Post-Traumatic Stress Disorder

RLS-01 /
Salvinorin A

Treatment-Resistant Depression
Revixia Life Sciences

VLS-01 /

Treatment-Resistant Depression
Viridia Life Sciences


Treatment-Resistant Depression

Discovery engines

Multiple lead indications
Multiple affiliate companies
Developing COMP360 therapy, with psychological support from specially trained therapists, for treatment-resistant depression. Positive Phase 2b topline data released on 11/09/21.
Developing DMX-1001, a formulation of noribogaine, as a potential at-home maintenance therapy for OUD. Preclinical stage.

Our Compounds


Hallucinogenic plants have been part of the human experience for thousands of years, with users aware of their potential for healing, transformation, and growth – as well as their dangers – since as far back as prehistory. Now that public attention has been captured by these extraordinary plants, it is more important than ever to understand the history, pharmacology, and therapeutic potential of psilocybin and other psychedelics.


accordion image LEARN MORE

Arketamine and esketamine are the R(-) and S(+) enantiomers of ketamine, a compound that has been used for everything from anesthesia and sedation to chronic pain and depression. Recently, esketamine as a nasal spray (Spravato™) made history as the first psychedelic-type substance approved by the U.S Food and Drug Administration (FDA) for treatment resistant depression.


accordion image LEARN MORE
Ibogaine & Noribogaine

Between 1991 and 2011, against the backdrop of a PR campaign aimed at convincing consumers that opioids were both safe and non-addictive, the U.S. saw a threefold spike in annual opioid prescription rates (from 76 to 219 million). Before long, misuse and addiction had exploded: In 2020, 3 million people in the U.S. have had or currently live with an OUD. The COVID-19 pandemic only deepened the opioid epidemic; overall drug overdoses shot up 30% in a year to 93,000of which close to 75% involved opioids. 


accordion image LEARN MORE

While psychedelics are an important component of the dawning mental healthcare revolution, it is critical to recognize that a comprehensive response to the global mental health crisis ought to be as diverse as possible. To this end, GABA Therapeutics is pursuing a natural approach based on the brain’s ability to correct imbalances that underlie many CNS disorders.


accordion image LEARN MORE

While psychedelics are an important component of the dawning mental healthcare revolution, non-psychedelics will also play key roles in both treatment and prevention of new cases. To this end, Neuronasal, Inc. is developing well-known and FDA-approved OTC compound N acetylcysteine (NAC) as a promising treatment for mild traumatic brain injury (mTBI) using intranasal administration for direct nose-to-brain delivery.


accordion image LEARN MORE
N, N-dimethyltryptamine

Even among psychedelics, DMT is extraordinary. Sometimes called the “spirit molecule”, this endogenous psychoactive compound occurs naturally in many plants and animals, and has been implicated in everything from dreaming to religious experiences. However, unlike most psychedelics, for example psilocybin, DMT exhibits extremely rapid onset and short duration of action.


accordion image LEARN MORE
MDMA derivative

Commonly known as ‘ecstasy’, one compound is seeing a resurgence not on the dancefloors, but rather in the clinics of researchers who have identified its value in treating a number of psychiatric disorders. With a Phase III trial now complete, many anticipate MDMA to be the first psychedelic-like drug to be approved by the FDA for the treatment of PTSD.


accordion image LEARN MORE

Despite limited scientific information, the DEA announced their intention to classify kratom, Mitragynine and 7-hydroxymitragynine as Schedule I on the Controlled Substance Act in 2016. Shortly after, a major push-back consisting of 23,000 written pleas from the general public, legislators and scientific community members challenged the DEA’s decision. For the first time in history, the DEA withdrew their intention to schedule a substance.


accordion image LEARN MORE
Salvinorin A

Salvinorin A is derived from the Mexican Lamiacae Salvia Divinorum, a member of the mint family. The plant has been an important part of ceremony and traditional healing for the Mazatec people of southern Mexico for centuries. Pharmacological study into the active ingredient didn’t take off until 1980s and 1990s, and the atypical mechanism of action is still not fully understood. But as the mysteries of this plant are revealed in the labdata indicate promise for a variety of indications.


accordion image LEARN MORE

Our Technologies


Introspect believes that high-quality digital combination therapies will increase the safety and effectiveness of many mental health drugs. Digital therapeutics (DTx) will provide personalized and scalable treatment to those who might not otherwise be able to access high-quality psychological care.


accordion image LEARN MORE

Psilocybin, ibogaine, and many other psychedelic substances have yielded remarkable early signals of their efficacy in treating everything from depression to various forms of addiction. And while Dr. Srinivas Rao, Chief Executive Officer of EntheogeniX Biosciences, shares the cautious optimism of many researchers, he’s careful to point out that these and other substances come with two significant obstacles…


accordion image LEARN MORE

InnarisBio specialized in drug formulation bringing its sol-gel based, intranasal excipient technology to atai. The novel technology may enable new drug formulations with unique and optimized modes of delivery across various active ingredients in the atai pipeline, as well as potential assets in the future. 


accordion image LEARN MORE

PsyProtix is taking a precision psychiatry approach to develop metabolomics-based biomarkers to stratify patients with treatment-resistant depression (TRD) and other mental health indicationsBy identifying patient subsets with unique metabolic profiles, PsyProtix will test mechanism-based treatments with the goal of improving overall outcomes.

accordion image LEARN MORE

Receive the latest news on atai and innovations in the space.